Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan-Feb:140-141:108975.
doi: 10.1016/j.nucmedbio.2024.108975. Epub 2024 Nov 22.

225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates

Affiliations

225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates

Stanislav V Ermolaev et al. Nucl Med Biol. 2025 Jan-Feb.

Abstract

Background: 213Bi is a short-lived radionuclide currently trialed for alpha therapy of various oncological diseases. A serious obstacle to the wide medical use is decay losses of 213Bi during a conventional synthesis of radiopharmaceuticals. In this work, we aimed to develop a two-column 225Aс/213Bi generator providing the accumulation of 213Bi separately from the parent 225Ac via continuous circular separation and decay of intermediate 221Fr. When attaining the transient equilibrium, 213Bi could be promptly extracted from the generator with an appropriate complexing agent, including chelator-protein bioconjugates.

Methods: Sorption behavior of Bi(III) ions onto the cross-linked dextran gel Sephadex G-25 was studied from solutions of hydrochloric and nitric acid, and from sodium chloride, sodium acetate and DTPA solutions. A bifunctional chelating agent p-SCN-Bn-DTPA was conjugated to an antibody Nimotuzumab specific to the epidermal growth factor receptor, and the procedure of 207,213Bi-DTPA-Nimotuzumab synthesis in the dextran gel medium was developed. The parameters of 225Aс/213Bi generator system were evaluated.

Results: The weight distribution ratios of Bi(III) adsorbed onto the Sephadex G-25 gel were obtained. Up to 85 % of 213Bi was accumulated in the second Sephadex-filled column of 225Aс/213Bi generator after four-hour circulation of 0.15 M NaCl (pH 5.5) solution. Having passed the solution of DTPA-Nimotuzumab bioconjugate through the second column, a fraction of 213Bi-DTPA-Nimotuzumab radioimmunoconjugate was produced with the radiochemical yield of 64 % ± 3 % (n = 6). High radionuclidic and radiochemical purity of product was achieved.

Conclusions: The circulating 225Aс/213Bi generator provides a 213Bi-labeled bioconjugate as a final product. While a conventional synthesis route including generator milking, bioconjugate labeling and size-exclusion purification takes >20 min, the duration of 213Bi-DTPA-Nimotuzumab production by the method proposed in this work is reduced to 6-8 min.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

MeSH terms

LinkOut - more resources